Microfluidic purification of T lymphocytes separated from blood for chimeric antigen receptor T-cell manufacturing

Elsemary, Mona T.; Maritz, Michelle F.; Smith, Leonard S.; Thierry, Benjamin

doi:10.1016/j.jcyt.2019.04.013

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rapidly screening for MAbs of surface receptors on breast cancer has been carried out in a microfluidic platform for use in clinical analysis [250]. The microfluidic purification of T lymphocytes separated from blood for chimeric antigen receptor T cell manufacturing has been demonstrated for CAR-T cell therapy reinjection [251], and the gene editing required to manufacture CAR-T cells has also been mechanized by microfluidic devices incorporating electroporation for CRISPR/CAS-9 modification [252]. Profiling T cell interaction and activation through serial encounters with antigen-presenting cells (APCs) has been accomplished in a microfluidic device mimicking the microenvironment of a lymph node [253].…”

Section: Drug Development and Deliverymentioning

confidence: 99%

Application of Microfluidic Systems for Breast Cancer Research

et al. 2022

View full text Add to dashboard Cite

Cancer is a disease in which cells in the body grow out of control; breast cancer is the most common cancer in women in the United States. Due to early screening and advancements in therapeutic interventions, deaths from breast cancer have declined over time, although breast cancer remains the second leading cause of cancer death among women. Most deaths are due to metastasis, as cancer cells from the primary tumor in the breast form secondary tumors in remote sites in distant organs. Over many years, the basic biological mechanisms of breast cancer initiation and progression, as well as the subsequent metastatic cascade, have been studied using cell cultures and animal models. These models, although extremely useful for delineating cellular mechanisms, are poor predictors of physiological responses, primarily due to lack of proper microenvironments. In the last decade, microfluidics has emerged as a technology that could lead to a paradigm shift in breast cancer research. With the introduction of the organ-on-a-chip concept, microfluidic-based systems have been developed to reconstitute the dominant functions of several organs. These systems enable the construction of 3D cellular co-cultures mimicking in vivo tissue-level microenvironments, including that of breast cancer. Several reviews have been presented focusing on breast cancer formation, growth and metastasis, including invasion, intravasation, and extravasation. In this review, realizing that breast cancer can recur decades following post-treatment disease-free survival, we expand the discussion to account for microfluidic applications in the important areas of breast cancer detection, dormancy, and therapeutic development. It appears that, in the future, the role of microfluidics will only increase in the effort to eradicate breast cancer.

show abstract

Section: Drug Development and Deliverymentioning

confidence: 99%

Application of Microfluidic Systems for Breast Cancer Research

et al. 2022

View full text Add to dashboard Cite

show abstract

“…One of the most promising technologies is cell viability detection inside a microfluidic chip . At present, there are many common methods for cell viability detection inside a microfluidic chip, such as trypan blue staining, , MTT assay, , and impedance assay. , However, some important technologies of cell viability detection inside a microfluidic chip have not been completely solved until now. One of the most critical technologies is the long-term culture of living cells with normal function, which is one of the bottlenecks in the development of biochip technology.…”

Section: Introductionmentioning

confidence: 99%

Study on Microfluidic Chip Flow Rate Uniformity for Cell Activity Detection

et al. 2023

View full text Add to dashboard Cite

During the cell viability detection process inside a microfluidic chip, the more uniform the distribution of medium flow rates, the higher the accuracy of detection results. In order to achieve this goal, a multichannel microfluidic chip with uniform distribution of medium flow rates has been successfully designed. The multichannel microfluidic chip is designed with cell injection channels, vascular network-shaped medium injection channels, buffer zones, and a culture chamber. The medium flow rates inside culture chambers of the multichannel microfluidic chip and the common single-channel microfluidic chip are compared by COMSOL Multiphysics software and particle velocimetry experiment. The simulation and experimental results show that the medium flow rate distribution inside the culture chamber of the multichannel microfluidic chip is more uniform and changes more smoothly. When the medium perfusion flow rate is 0.5 μL/min, the maximum flow rate difference inside the culture chamber of the single-channel microfluidic chip is more than 13 times that of the multichannel microfluidic chip. Therefore, the multichannel microfluidic chip can ensure a uniform supply of medium inside the culture chamber, which is beneficial to improve the accuracy of cell viability detection.

show abstract

Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies

Ngo

Kuo

2023

Biomicrofluidics

View full text Add to dashboard Cite

Despite several extraordinary improvements in cancer immunotherapy, its therapeutic effectiveness against many distinct cancer types remains mostly limited and requires further study. Different microfluidic-based cancer immunotherapy-on-a-chip (ITOC) systems have been developed to help researchers replicate the tumor microenvironment and immune system. Numerous microfluidic platforms can potentially be used to perform various on-chip activities related to early clinical cancer immunotherapy processes, such as improving immune checkpoint blockade therapy, studying immune cell dynamics, evaluating cytotoxicity, and creating vaccines or organoid models from patient samples. In this review, we summarize the most recent advancements in the development of various microfluidic-based ITOC devices for cancer treatment niches and present future perspectives on microfluidic devices for immunotherapy research.

show abstract

Microfluidic purification of T lymphocytes separated from blood for chimeric antigen receptor T-cell manufacturing

Cited by 3 publications

References 0 publications

Application of Microfluidic Systems for Breast Cancer Research

Application of Microfluidic Systems for Breast Cancer Research

Study on Microfluidic Chip Flow Rate Uniformity for Cell Activity Detection

Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies

Contact Info

Product

Resources

About